Clin2
NCT07191483Possibly a fitRecruiting

Study of KYN-5356 for cognitive problems in schizophrenia

Cognitive Impairment Associated With Schizophrenia (CIAS)

Part of Mental health clinical trials.

This trial tests an investigational drug, KYN-5356, to see if it can improve thinking and memory problems in adults with schizophrenia. You may join if your schizophrenia is stable and you take only one antipsychotic medication.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
150 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You have been diagnosed with schizophrenia for at least 1 year.
  • Your schizophrenia symptoms have been stable for at least 8 weeks.
  • You are between 18 and 55 years old.
  • You take only one antipsychotic medication and have been on the same dose for at least 2 months.
  • Your body mass index (BMI) is between 18 and 40.
  • You do not have a moderate to severe substance use disorder (other than nicotine or caffeine).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07446478Recruiting
TIS for improving thinking problems in schizophrenia

This trial tests if a brain stimulation technique called transcranial electrical stimulation (TIS) can help improve cognitive problems (like memory and attention) in people with schizophrenia. You may join if you are between 18 and 50, have had schizophrenia for no more than 8 years, take 1-2 antipsychotic medicines, and have some trouble with daily activities.

Changsha, Hunan
NCT07114874Recruiting· Phase 3
A long-term study of a new drug for schizophrenia

This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.

Bryant, Arkansas
NCT07084831Not yet recruiting· Phase 3
Study of Xanomeline/Trospium for memory in schizophrenia

This trial tests if a new treatment, xanomeline/trospium (XT), can help improve thinking and memory problems in adults with schizophrenia. You would take XT as a tablet alongside your current medication for up to 52 weeks.

Innsbruck
NCT06021197Recruiting· Phase 2
NMDA-enhancing treatment for cognitive symptoms in schizophrenia

This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.

Taichung
NCT07585383Not yet recruiting· Phase 1
Safety study of KR23248 in healthy adults

This is an early-stage study testing a new experimental drug called KR23248 in healthy volunteers to see if it is safe and how the body processes it. Researchers want to understand potential side effects and how the drug moves through your system.

NCT07263022Recruiting· Phase 3
Cognitive Training for Early Psychosis Study

This study tests whether a cognitive training program can help young adults with recent psychosis improve their thinking and memory skills. It involves brain scans and cognitive exercises.

Minneapolis, Minnesota

Hear when a new Cognitive Impairment Associated With Schizophrenia (CIAS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.